<!DOCTYPE html><html lang="en-us" >

<head>

  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <meta name="generator" content="Source Themes Academic 4.8.0">

  

  
  
  
  
  
  

  

  
  
  
    
  
  <meta name="description" content="CD4 molecule
Gene Context Sentence Table 2. Analysis of context sentence of CD4 gene in 45 abstracts.   PMID  Gene Context Sentence      12408739  In HIV-associated Kaposi’s sarcoma, rIFNalpha is active as monotherapy and in combination with antiretroviral agents, especially in patients with CD4 counts &gt;200/mm(3), no prior opportunistic infections and nonvisceral disease.">

  
  <link rel="alternate" hreflang="en-us" href="/mesothelioma/genepanel/920/gene_context/">

  


  
  
  
  <meta name="theme-color" content="#2962ff">
  

  
  

  
  
  
  
    
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/academicons/1.8.6/css/academicons.min.css" integrity="sha256-uFVgMKfistnJAfoCUQigIl+JfUaP47GrRKjf6CTPVmw=" crossorigin="anonymous">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.12.0-1/css/all.min.css" integrity="sha256-4w9DunooKSr3MFXHXWyFER38WmPdm361bQS/2KUWZbU=" crossorigin="anonymous">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/fancybox/3.5.7/jquery.fancybox.min.css" integrity="sha256-Vzbj7sDDS/woiFS3uNKo8eIuni59rjyNGtXfstRzStA=" crossorigin="anonymous">

    
    
    
      
    
    
      
      
        
          <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/9.18.1/styles/github.min.css" crossorigin="anonymous" title="hl-light">
          <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/9.18.1/styles/dracula.min.css" crossorigin="anonymous" title="hl-dark" disabled>
        
      
    

    

    

    
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
        <script src="https://cdnjs.cloudflare.com/ajax/libs/lazysizes/5.1.2/lazysizes.min.js" integrity="sha256-Md1qLToewPeKjfAHU1zyPwOutccPAm5tahnaw7Osw0A=" crossorigin="anonymous" async></script>
      
    
      

      
      

      
    
      

      
      

      
    
      

      
      
        
      

      
    
      

      
      

      
    

  

  
  
  
  <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Montserrat:400,700%7CRoboto:400,400italic,700%7CRoboto+Mono&display=swap">
  

  
  
  
  
  <link rel="stylesheet" href="/mesothelioma/css/academic.css">

  





<script async src="https://www.googletagmanager.com/gtag/js?id=google_analytics_ID"></script>
<script>
  window.dataLayer = window.dataLayer || [];

  function gtag() {
      dataLayer.push(arguments);
  }

  function trackOutboundLink(url, target) {
    gtag('event', 'click', {
         'event_category': 'outbound',
         'event_label': url,
         'transport_type': 'beacon',
         'event_callback': function () {
           if (target !== '_blank') {
             document.location = url;
           }
         }
    });
    console.debug("Outbound link clicked: " + url);
  }

  function onClickCallback(event) {
    if ((event.target.tagName !== 'A') || (event.target.host === window.location.host)) {
      return;
    }
    trackOutboundLink(event.target, event.target.getAttribute('target'));  
  }

  gtag('js', new Date());
  gtag('config', 'google_analytics_ID', {});

  
  document.addEventListener('click', onClickCallback, false);
</script>


  


  
  

  

  <link rel="manifest" href="/mesothelioma/index.webmanifest">
  <link rel="icon" type="image/png" href="/mesothelioma/images/icon_hu3365e08ad5ef6cb6d886bc511b9ad2b3_313689_32x32_fill_lanczos_center_2.png">
  <link rel="apple-touch-icon" type="image/png" href="/mesothelioma/images/icon_hu3365e08ad5ef6cb6d886bc511b9ad2b3_313689_192x192_fill_lanczos_center_2.png">

  <link rel="canonical" href="/mesothelioma/genepanel/920/gene_context/">

  
  
  
  
  
  
  
    
    
  
  
  <meta property="twitter:card" content="summary">
  
  <meta property="og:site_name" content="mesothelioma">
  <meta property="og:url" content="/mesothelioma/genepanel/920/gene_context/">
  <meta property="og:title" content="CD4 | mesothelioma">
  <meta property="og:description" content="CD4 molecule
Gene Context Sentence Table 2. Analysis of context sentence of CD4 gene in 45 abstracts.   PMID  Gene Context Sentence      12408739  In HIV-associated Kaposi’s sarcoma, rIFNalpha is active as monotherapy and in combination with antiretroviral agents, especially in patients with CD4 counts &gt;200/mm(3), no prior opportunistic infections and nonvisceral disease."><meta property="og:image" content="/mesothelioma/images/icon_hu3365e08ad5ef6cb6d886bc511b9ad2b3_313689_512x512_fill_lanczos_center_2.png">
  <meta property="twitter:image" content="/mesothelioma/images/icon_hu3365e08ad5ef6cb6d886bc511b9ad2b3_313689_512x512_fill_lanczos_center_2.png"><meta property="og:locale" content="en-us">
  
    
      <meta property="article:published_time" content="2019-05-05T00:00:00&#43;01:00">
    
    <meta property="article:modified_time" content="2019-05-05T00:00:00&#43;01:00">
  

  



  


  


  





  <title>CD4 | mesothelioma</title>

</head>

<body id="top" data-spy="scroll" data-offset="70" data-target="#TableOfContents" >

  <aside class="search-results" id="search">
  <div class="container">
    <section class="search-header">

      <div class="row no-gutters justify-content-between mb-3">
        <div class="col-6">
          <h1>Search</h1>
        </div>
        <div class="col-6 col-search-close">
          <a class="js-search" href="#"><i class="fas fa-times-circle text-muted" aria-hidden="true"></i></a>
        </div>
      </div>

      <div id="search-box">
        
        <input name="q" id="search-query" placeholder="Search..." autocapitalize="off"
        autocomplete="off" autocorrect="off" spellcheck="false" type="search">
        
      </div>

    </section>
    <section class="section-search-results">

      <div id="search-hits">
        
      </div>

    </section>
  </div>
</aside>


  







<nav class="navbar navbar-expand-lg navbar-light compensate-for-scrollbar" id="navbar-main">
  <div class="container">

    
    <div class="d-none d-lg-inline-flex">
      <a class="navbar-brand" href="/mesothelioma/">mesothelioma</a>
    </div>
    

    
    <button type="button" class="navbar-toggler" data-toggle="collapse"
            data-target="#navbar-content" aria-controls="navbar" aria-expanded="false" aria-label="Toggle navigation">
    <span><i class="fas fa-bars"></i></span>
    </button>
    

    
    <div class="navbar-brand-mobile-wrapper d-inline-flex d-lg-none">
      <a class="navbar-brand" href="/mesothelioma/">mesothelioma</a>
    </div>
    

    
    
    <div class="navbar-collapse main-menu-item collapse justify-content-start" id="navbar-content">

      
      <ul class="navbar-nav d-md-inline-flex">
        

        

        
        
        
          
        

        
        
        
        
        
        

        <li class="nav-item">
          <a class="nav-link " href="/mesothelioma/syntax/"><span>Syntax</span></a>
        </li>

        
        

        

        
        
        
          
        

        
        
        
        
        
        

        <li class="nav-item">
          <a class="nav-link  active" href="/mesothelioma/genepanel/"><span>Gene Panel</span></a>
        </li>

        
        

        

        
        
        
          
        

        
        
        
        
        
        

        <li class="nav-item">
          <a class="nav-link " href="/mesothelioma/drugpanel/"><span>Drug Panel</span></a>
        </li>

        
        

        

        
        
        
          
        

        
        
        
        
        
        

        <li class="nav-item">
          <a class="nav-link " href="/mesothelioma/tissuepanel/"><span>Tissue Panel</span></a>
        </li>

        
        

        

        
        
        
          
        

        
        
        
        
        
        

        <li class="nav-item">
          <a class="nav-link " href="/mesothelioma/syntax_summary/"><span>Literature Consensus</span></a>
        </li>

        
        

        

        
        
        
          
        

        
        
        
        
        
        
          
          
          
            
          
          
        

        <li class="nav-item">
          <a class="nav-link " href="/mesothelioma/#about"><span>Contact</span></a>
        </li>

        
        

      

        
      </ul>
    </div>

    <ul class="nav-icons navbar-nav flex-row ml-auto d-flex pl-md-2">
      
      <li class="nav-item">
        <a class="nav-link js-search" href="#"><i class="fas fa-search" aria-hidden="true"></i></a>
      </li>
      

      

      

    </ul>

  </div>
</nav>


  

<div class="container-fluid docs">
  <div class="row flex-xl-nowrap">
    <div class="col-12 col-md-3 col-xl-2 docs-sidebar">
      





  
    
  




<form class="docs-search d-flex align-items-center">
  <button class="btn docs-toggle d-md-none p-0 mr-3" type="button" data-toggle="collapse" data-target="#docs-nav" aria-controls="docs-nav" aria-expanded="false" aria-label="Toggle section navigation">
    <span><i class="fas fa-bars"></i></span>
  </button>

  
  <input name="q" type="search" class="form-control" placeholder="Search..." autocomplete="off">
  
</form>

<nav class="collapse docs-links" id="docs-nav">
  

  
  
  
  
  <div class="docs-toc-item">
    <a class="docs-toc-link" href="/mesothelioma/genepanel/920/info/">Overview</a>
    <ul class="nav docs-sidenav">
      
      <li >
        <a href="/mesothelioma/genepanel/920/gene_expression/">Gene Expression</a>
      </li>
      
      <li class="active">
        <a href="/mesothelioma/genepanel/920/gene_context/">Gene Context</a>
      </li>
      
      <li >
        <a href="/mesothelioma/genepanel/920/clinvar/">ClinVar</a>
      </li>
      
      <li >
        <a href="/mesothelioma/genepanel/920/geo/">Geo DataSet</a>
      </li>
      
    </ul>
    

  </div>
  
  
</nav>

    </div>

    

    <main class="col-12 col-md-9 col-xl-8 py-md-3 pl-md-5 docs-content" role="main">

      <article class="article">

        <div class="docs-article-container">
          <h1>CD4</h1>

          <div class="article-style">
            
<script src="/mesotheliomarmarkdown-libs/kePrint/kePrint.js"></script>


<hr />
<p>CD4 molecule</p>
<hr />
<div id="gene-context-sentence" class="section level2">
<h2>Gene Context Sentence</h2>
<br>
<p style="font-size:12px" align="center">
<strong>Table 2.</strong> Analysis of context sentence of CD4 gene in 45 abstracts.
</p>
<table class="table table-striped" style="width: auto !important; margin-left: auto; margin-right: auto;">
<thead>
<tr>
<th style="text-align:center;position: sticky; top:0; background-color: #FFFFFF;">
PMID
</th>
<th style="text-align:center;position: sticky; top:0; background-color: #FFFFFF;">
Gene Context Sentence
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:center;">
<a href="/publication/12408739" target="_blank">12408739</a>
</td>
<td style="text-align:center;">
In HIV-associated Kaposi’s sarcoma, rIFNalpha is active as monotherapy and in combination with antiretroviral agents, especially in patients with CD4 counts &gt;200/mm(3), no prior opportunistic infections and nonvisceral disease. rIFNalpha has shown encouraging results when used in combination with retinoids in the chemoprevention of head and neck squamous cell cancers.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/15230209" target="_blank">15230209</a>
</td>
<td style="text-align:center;">
The aim of the study was to evaluate: 1) the frequency of lymphocyte predominance in different malignant and non-malignant pleural effusions; 2) lymphocyte phenotype and the ratio between helper (CD4+) and cytotoxic/suppressor (CD8+) lymphocytes in malignant and non-malignant effusions. […] For lymphocyte subpopulations analysis, the monoclonal antibodies anti-CD4 and anti-CD8 and APAAP method was used. […] We observed lower percentage of CD4+ lymphocytes (47%) and higher percentage of CD8+ (39%) lymphocytes in malignant when compared to non-malignant fluids (58% vs 31% respectively). […] The CD4+/CD8+ ratio was significantly lower in pleural fluid in cases with neoplastic disease when compared to benign cause of pleural involvement (1.03 vs 1.85).
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/15846066" target="_blank">15846066</a>
</td>
<td style="text-align:center;">
Immunotherapy against a variety of malignancies, including pleural-based malignancies, has shown promise in animal models and early human clinical trials, but successful efforts will need to address immunosuppressive factors of the tumor and host, particularly certain cytokines and CD4(+) CD25(+) regulatory T cells (Treg). […] Although a high prevalence of functionally suppressive CD4(+) CD25(+) T cells was found in carcinomatous pleural effusions, mesothelioma pleural effusions contained significantly fewer CD4(+) CD25(+) T cells. […] However, there is clear patient-to-patient variability and occasional mesothelioma patients with high percentages of CD4(+) CD25(+) pleural effusion T cells and low percentages of CD8(+) CD25(+) pleural effusion T cells can be identified.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/16540497" target="_blank">16540497</a>
</td>
<td style="text-align:center;">
There was a massive influx of CD4+ and CD8+ T-lymphocytes and macrophages, but not of dendritic cells, in human mesothelioma biopsies. […] It was further demonstrated that human mesothelioma tissue contained significant amounts of Foxp3+CD4+CD25+ regulatory T-cells.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/17439834" target="_blank">17439834</a>
</td>
<td style="text-align:center;">
The expression of leukocyte markers (CD3, CD4, CD8, CD14, CD16, and CD19) and chemokine receptors (CXCR1, CXCR4, CCR2, CCR5, and CCR7) was studied in 11 MM and 16 RM specimens using flow cytometry.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/17974153" target="_blank">17974153</a>
</td>
<td style="text-align:center;">
Circulating CD4+ and CD8+ T cells were counted using two-colour flowcytometry. […] Flowcytometric analysis exhibited a significant increase in the mean percentage of circulating CD4+ T cell count in mesothelioma (56.7% +/- 6.99) versus control (43% +/- 1.58), p &lt; 0.001. […] CD4/CD8 ratio was significantly increased versus control (2.06 +/- 0.57 versus 1.3 +/- 0.02 p &lt; 0.05).
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/18374762" target="_blank">18374762</a>
</td>
<td style="text-align:center;">
We performed an immunohistochemical analysis of 32 extrapleural pneumonectomy specimens to assess the distribution of T-cell subtypes (CD3(+), CD4(+), and CD8(+)), regulatory subtypes (CD25(+) and FOXP3(+)), and memory subtype (CD45RO(+)) within the tumor. […] Patients presenting high levels of CD4(+) or CD25(+) tumor-infiltrating lymphocytes or low levels of CD45RO(+) also demonstrated a trend toward shorter survival.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/19935800" target="_blank">19935800</a>
</td>
<td style="text-align:center;">
Tumour-infiltrating lymphocytes (CD4, CD8, Foxp3), mast cells (MCs) (tryptase and chymase), microvessel count (MVC) and VEGF were determined by immunohistochemistry in two series of MPM patients: 60 patients treated with intra-pleural preoperative IL-2 and 33 patients untreated.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/20053697" target="_blank">20053697</a>
</td>
<td style="text-align:center;">
CD8+, CD4+ and Foxp3+ tumor-infiltrating lymphocytes, tryptase and chymase mast cells (MCs), CD34, number of microvessels and vascular endothelial growth factor were determined by immunohistochemistry.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/20532500" target="_blank">20532500</a>
</td>
<td style="text-align:center;">
Immune responses were evaluated by DTH, CD4 T-cell proliferation, CD8 T-cell interferon gamma release, intracellular cytokine staining, WT1 peptide MHC-tetramer staining, and cytotoxicity against WT1 positive tumor cells. […] Six out of nine patients tested demonstrated CD4 T-cell proliferation to WT1 specific peptides, and five of the six HLA-A0201 patients tested mounted a CD8 T-cell response.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/20548032" target="_blank">20548032</a>
</td>
<td style="text-align:center;">
CD4(+)CD25(+) regulatory T cells (Tregs) can promote the growth of some tumors, but it is unknown whether this is true for all tumors, including malignant pleural mesothelioma.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/20567822" target="_blank">20567822</a>
</td>
<td style="text-align:center;">
HLA class I expression and TILs (CD4(+), CD8(+), and NK cells) were detected by immunohistochemistry in a series of 44 MPM cases. […] The density of CD4(+) and CD8(+) TILs were strongly correlated (R = 0.76, p &lt; 0.001).
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/20853778" target="_blank">20853778</a>
</td>
<td style="text-align:center;">
Recent studies have demonstrated that asbestos acts on peripheral T cells as superantigen and that in malignant mesothelioma patients there is an overexpression of the Bcl-2 gene on peripheral CD4+ T cells.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/21357438" target="_blank">21357438</a>
</td>
<td style="text-align:center;">
In this study, to confirm that these findings are suitable for clinical translation, surface CXCR3 and IFN-γ expression were analyzed using freshly isolated human CD4(+) T cells derived from healthy donors and patients with pleural plaque (PP) or MM. […] Additionally, CXCR3 expression in CD4(+) T cells from PPs and MMs was significantly reduced compared with that from healthy donors, and CD4(+) T cells from patients with MMs exhibited a marked reduction in IFN-γ mRNA levels after stimulation in vitro. […] Moreover, CD4(+)CXCR3(+) T cells in lymphocytes from MMs showed a tendency for an inverse correlation with its ligand CXCL10/IP10 in plasma.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/21642867" target="_blank">21642867</a>
</td>
<td style="text-align:center;">
The proportion of CD4+ CD25+Foxp3+ Tregs, CD4+, and CD8+ T cells in the tumor, spleen, draining lymph node, and peripheral blood from tumor-bearing mice was determined by using flow cytometry, and gene expression of activated T-cell-related cytokines was quantified by enzyme-linked immunosorbent assay and reverse-transcribed polymerase chain reaction. […] The CD4+CD25+Foxp3+ Tregs in tumor and lymphoid organs were almost completely depleted, whereas the CD4+ or CD8+ T cells did not change.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/22684580" target="_blank">22684580</a>
</td>
<td style="text-align:center;">
According to the histological types, we measured changes in the frequencies of CD4⁺ CD8⁺ (DP) and CD4⁻CD8⁻ (DN), but not in the cytokine profiles (IFN-γ/IL-4 expression).
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/23816056" target="_blank">23816056</a>
</td>
<td style="text-align:center;">
Blood CD4+ or CD8+ T cells percentages were similar in all groups of patients or healthy subjects. […] Whereas pleural fluid from healthy controls contained mainly CD8+ T cells, benign or malignant pleural effusions included mainly CD4+ T cells. […] In contrast, there was a striking and selective recruitment of central memory CD4+ T cells in MPE, but not of effector cells CD8+ T cells or NK cells in the pleural fluid as one would expect in order to obtain an efficient immune response.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/24179709" target="_blank">24179709</a>
</td>
<td style="text-align:center;">
GC1008 had no effect in the expression of NK, CD4<sup>+</sup>, or CD8<sup>+</sup> T cell activating and inhibitory markers, other than a decrease in the expression of 2B4 and DNAM-1 on NK cells.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/25123375" target="_blank">25123375</a>
</td>
<td style="text-align:center;">
Mice in the treatment group had a significant increase in the percentage of activated CD4(+) and CD8(+) T cells in tumour-draining lymph nodes.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/25378643" target="_blank">25378643</a>
</td>
<td style="text-align:center;">
This therapeutic efficacy was dependent on early CD4(+) T cell activation associated with a higher intratumoral CD4/CD8 cell ratios and CD28-dependent CD4(+) T cell-mediated cytotoxicity.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/26155428" target="_blank">26155428</a>
</td>
<td style="text-align:center;">
According to univariate analyses, high densities of tumoral CD4- and CD20-expressing lymphocytes were associated with better outcomes.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/2646076" target="_blank">2646076</a>
</td>
<td style="text-align:center;">
In many effusions in this study, a concomitant T-lymphocytosis was observed with a non-specific increase in the CD4/CD8 ratio, as known for other pleural diseases.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/26485154" target="_blank">26485154</a>
</td>
<td style="text-align:center;">
This provides accurate quantification of seven immune parameters: total lymphocytes, monocytes and neutrophils, as well as the T-cell subsets CD4 and CD8, B-cells and Natural Killer cells.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/26652184" target="_blank">26652184</a>
</td>
<td style="text-align:center;">
Low-dose cyclophosphamide reduced the percentage of regulatory T cells of total CD4 cells in peripheral blood from 9.43 (range, 4.34-26.10) to 4.51 (range, 0.27-10.30) after 7 days of cyclophosphamide treatment (P = 0.02).
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/27856426" target="_blank">27856426</a>
</td>
<td style="text-align:center;">
Compared with PD-L1-negative tumors, PD-L1-positive tumors had significantly more infiltrating CD45<sup>+</sup> immune cells, a significantly higher proportion of infiltrating CD3<sup>+</sup> T cells, and a significantly higher percentage of CD3<sup>+</sup> cells displaying the activated HLA-DR<sup>+</sup>/CD38<sup>+</sup> phenotype. […] PD-L1-positive tumors also had a significantly higher proportion of proliferating CD8<sup>+</sup> T cells, a higher fraction of FOXP3<sup>+</sup>/CD4<sup>+</sup> Tregs, and increased expression of PD-1 and TIM-3 on CD4<sup>+</sup> and CD8<sup>+</sup> T cells.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/27878235" target="_blank">27878235</a>
</td>
<td style="text-align:center;">
Based on our hypothesis in which continuous exposure to asbestos of immune cells cause reduction of antitumor immunity, the decrease of natural killer cell killing activity with reduction of NKp46 activating receptor expression, inhibition of cytotoxic T cell clonal expansion, reduced CXCR3 chemokine receptor expression and production of interferon-γ production in CD4+ T cells were reported using cell line models, freshly isolated peripheral blood immune cells from health donors as well as asbestos exposed patients such as pleural plaque and mesothelioma.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/28051835" target="_blank">28051835</a>
</td>
<td style="text-align:center;">
Chemokine (C-X-C motif) receptor (CXCR)3 expression in CD4(+) T cells from pleural plaques and MMs was significantly decreased compared with that from healthy donors suggesting that CXCR3, IFN-γ, and IP-10 may be candidates to detect and monitor disease status.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/28197385" target="_blank">28197385</a>
</td>
<td style="text-align:center;">
We stained for PD-1, PD-L1, TIM-3, LAG-3, CD4, CD8, CD45RO, granzyme B, FoxP3 and CD68. […] CD45RO expression in the stroma was an independent negative predictive factor for response on chemotherapy, while CD4 and TIM-3 expression in lymphoid aggregates were independent prognostic factors for better outcome.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/28498408" target="_blank">28498408</a>
</td>
<td style="text-align:center;">
Additionally, analysis of T helper cells showed that surface CXCR3, chemokine receptor, and the productive potential of interferon (IFN)γ were reduced following asbestos exposure in an in vitro cell line model and in peripheral CD4+ cells of asbestos-exposed patients. […] Following activation with T-cell receptor and co-culture with various concentrations of chrysotile fibers using freshly isolated CD4+ surface CXCR3 positive and negative fractions, the intracellular expression of CXCR3, IFNγ and IL-17 remained unchanged when co-cultured with chrysotile. […] However, subsequent re-stimulation with phorbol 12-myristate 13-acetate (PMA) and ionomycin resulted in enhanced IL-17 production and expression, particularly in CD4+ surface CXCR3 positive cells.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/29163783" target="_blank">29163783</a>
</td>
<td style="text-align:center;">
We found CD4<sup>+</sup> and CD8<sup>+</sup> T cells, B cells, macrophages, natural killer cells, dendritic cells and tumor cells in the fluids. […] Moreover, we identified two MPM effusion-related factors with clinical value: CD4+ T cells were significantly correlated with better response to chemotherapy, while the percentage of PD-L1<sup>+</sup> podoplanin (PDPN)<sup>+</sup> tumor cells is a significant prognostic factor for worse outcome.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/29399399" target="_blank">29399399</a>
</td>
<td style="text-align:center;">
BBIs reduced the expression of the immune checkpoint ligand PD-L1 in MPM cells; while both CD8<sup>+</sup> and CD4<sup>+</sup> T-lymphocytes co-cultured with JQ1-treated MPM cells decreased PD-1 expression, suggesting a disruption of the immune-suppressive PD-L1/PD-1 axis.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/29419731" target="_blank">29419731</a>
</td>
<td style="text-align:center;">
On the other hand, inflammatory changes such as expression of MMP7, CXCR5, CXCL13 and CD44 was found to be markedly higher in sublines continuously exposed to asbestos compared with original MT-2 cells. […] Finally, regarding peripheral T cells from healthy donors (HD) and asbestos-exposed patients with pleural plaque (PP) or malignant pleural mesothelioma (MPM), following stimulation of CD4+ T cells, T cells from MPM patients showed reduced potential of interferon (IFN)-γ expression.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/29514216" target="_blank">29514216</a>
</td>
<td style="text-align:center;">
Sarcomatoid/biphasic samples were characterized by higher CD8+ T lymphocytes and PD-L1 expression on tumor cells, while epithelioid showed higher peritumoral CD4+ T and CD20+ B lymphocytes.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/30245692" target="_blank">30245692</a>
</td>
<td style="text-align:center;">
T cell receptor (TCR) diversity was evaluated by <i>TCRB</i> gene PCR assays. <b>Results:</b> We observed an increase in the numbers of B cells, CD4 and CD8 T cells, but not NK cells at 6 weeks post-treatment. […] Notably, we did observe enhanced proportions of CD4 T cells expressing HLA-DR, PD-1 (at 2 weeks after onset of treatment) and ICOS (6 weeks) and a CD8 T cell population expressing LAG3 (2 weeks). <b>Discussion:</b> DC immunotherapy using allogeneic tumor lysate resulted in enhanced frequencies of B cells and T cells in blood. […] Interestingly, frequencies of CD4 T cells expressing activation markers and PD-1 were increased.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/30518402" target="_blank">30518402</a>
</td>
<td style="text-align:center;">
Both CD8<sup>+</sup> and CD4<sup>+</sup> T cells from effusion showed increased expression of T cell inhibitory receptors PD-1, LAG-3 and Tim-3 compared to blood.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/31078776" target="_blank">31078776</a>
</td>
<td style="text-align:center;">
The cutoffs of intratumor T-regulatory (&gt;1.1%) cells, M2-macrophages (&gt;36%), granulocytic and monocytic myeloid-derived suppressor cells (MDSC; &gt;5.1% and 4.2%, respectively), CD4 molecule-positive (CD4<sup>+</sup>) programmed death 1-positive (PD-1<sup>+</sup>) (&gt;5.2%) and CD8<sup>+</sup>PD-1<sup>+</sup> (6.4%) cells, CD4<sup>+</sup> lymphocyte activating 3-positive (LAG-3<sup>+</sup>) (&gt;2.8% ) and CD8<sup>+</sup>LAG-3<sup>+</sup> (&gt;2.8%) cells, CD4<sup>+</sup> T cell immunoglobulin and mucin domain 3-positive (TIM-3<sup>+</sup>) (&gt;2.5%), and CD8<sup>+</sup>TIM-3<sup>+</sup> (&gt;2.6%) cells discriminated MPM from pleuritis with 100% sensitivity and 89% specificity. […] By contrast, the intratumor T-regulatory and MDSC levels significantly correlated with progression-free and overall survival, the PD-1<sup>+</sup>/LAG-3<sup>+</sup>/TIM-3<sup>+</sup> CD4<sup>+</sup> tumor-infiltrating lymphocytes correlated with overall survival.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/31428531" target="_blank">31428531</a>
</td>
<td style="text-align:center;">
Hypofunction was associated with higher numbers of CD4 regulatory T cells (Tregs) and with expression of the inhibitory receptor TIGIT.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/31428586" target="_blank">31428586</a>
</td>
<td style="text-align:center;">
Vaccination of mice with p-Tvax led to antigen-specific immune responses that involved both CD8<sup>+</sup> and CD4<sup>+</sup> T cells, which exhibited cytolytic activity against MM cells <i>in vitro</i>. […] In mice carrying MM tumors, p-Tvax increased tumor infiltration of CD4<sup>+</sup> T cells. […] Mice treated with this combination immunotherapy displayed higher numbers of tumor-infiltrating CD8<sup>+</sup> and CD4<sup>+</sup> T cells and reduced T regulatory cells in tumors.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/31639216" target="_blank">31639216</a>
</td>
<td style="text-align:center;">
In this study, 172 well-characterised primary diffuse MPM tumours including epithelioid (n = 145), biphasic (n = 15), and sarcomatoid (n = 12) histotypes were evaluated immunohistochemically for CD70, CD27, CD3, CD4, CD8, CD56, PDCD1 (PD-1), and FOXP3 expression. […] Patients with MPM containing a higher number of CD3<sup>+</sup> (p &lt; 0.01), CD4<sup>+</sup> (p &lt; 0.01), CD8<sup>+</sup> (p &lt; 0.01), or FOXP3<sup>+</sup> (p &lt; 0.01) tumour-infiltrating lymphoid cells (TILs) showed significantly worse clinical outcomes.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/31681580" target="_blank">31681580</a>
</td>
<td style="text-align:center;">
Moreover, the influence of Ki67 and CD4 T-cell infiltration on OS were more pronounced among patients with high gC1qR expression. <b>Conclusion:</b> This is the first description of gC1qR expression in MPM.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32234848" target="_blank">32234848</a>
</td>
<td style="text-align:center;">
We separately profiled PD1<sup>+</sup> and PD1<sup>-</sup>CD4<sup>+</sup> and CD8<sup>+</sup> T cells, as well as Tregs and analyzed 70 000 TCRβ sequences per patient. […] DC-therapy primarily induced TCRβ repertoire changes in the PD1<sup>+</sup>CD4<sup>+</sup> and PD1<sup>+</sup>CD8<sup>+</sup> T cell fractions. […] Conversion from a PD1<sup>-</sup> to a PD1<sup>+</sup> phenotype was significantly more frequent in CD8<sup>+</sup> T cells than in CD4<sup>+</sup> T cells. […] Hereby, the number of expanding PD1<sup>+</sup>CD8<sup>+</sup> T cell clones-and not expanding PD1<sup>+</sup>CD4<sup>+</sup> T cell clones following immunotherapy positively correlated with overall survival, progression-free survival and reduction of tumor volume.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32526602" target="_blank">32526602</a>
</td>
<td style="text-align:center;">
Although the effect was associated with CD8<sup>+</sup> and CD4<sup>+</sup> T cells in tumors, the number of Foxp3<sup>+</sup> cells was not reduced but rather increased.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32676326" target="_blank">32676326</a>
</td>
<td style="text-align:center;">
Multiplex immunohistochemistry was used to assess proportions of CD4, CD8, CD45RO and FOXP3 positive infiltrates in MPM and their association with progression free (PFS) and overall (OS) survival post immunotherapy. […] Of the subtypes, sarcomatoid patients displayed the greatest median PFS and OS (&gt;28 months) post ICI compared to the epithelioid subtype (3 and 11 months respectively), which correlated with higher proportions of infiltrating CD8<sup>+</sup>, CD45RO<sup>+</sup> and CD8<sup>+</sup>CD45RO<sup>+</sup> cells. […] High proportions of T lymphocytes and CD45RO<sup>+</sup> cells were associated with prolonged mPFS and mOS in sarcomatoid patients treated with ICI immunotherapy.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/8833988" target="_blank">8833988</a>
</td>
<td style="text-align:center;">
Using analysis of mononuclear immunophenotyping, CD3+, CD4+, and CD8+ cells did not show any significant difference between the two groups.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/9468586" target="_blank">9468586</a>
</td>
<td style="text-align:center;">
A slight decrease in CD4-positive subset of lymphocytes was observed after rIL-2 treatment.
</td>
</tr>
</tbody>
</table>
<hr />
</div>

          </div>

          



          
        </div>

        <div class="body-footer">
          
          

          
        </div>

      </article>

      <footer class="site-footer">
  
  <p class="powered-by">
    
      <a href="/mesothelioma/privacy/">Privacy Policy</a>
    
    
        &middot; 
      <a href="/mesothelioma/terms/">Terms</a>
    
    
        &middot; 
      <a href="/mesothelioma/supp/faq/">FAQ</a>
    
  </p>
  

  <p class="powered-by">
    BioHub - UFPE &middot; 

    Powered by the
    <a href="https://sourcethemes.com/academic/" target="_blank" rel="noopener">Academic theme</a> for
    <a href="https://gohugo.io" target="_blank" rel="noopener">Hugo</a>.

    
  </p>
</footer>


    </main>
  </div>
</div>


      

    
    
    
      <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery/3.4.1/jquery.min.js" integrity="sha256-CSXorXvZcTkaix6Yvo6HppcZGetbYMGWSFlBw8HfCJo=" crossorigin="anonymous"></script>
      <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery.imagesloaded/4.1.4/imagesloaded.pkgd.min.js" integrity="sha256-lqvxZrPLtfffUl2G/e7szqSvPBILGbwmsGE1MKlOi0Q=" crossorigin="anonymous"></script>
      <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery.isotope/3.0.6/isotope.pkgd.min.js" integrity="sha256-CBrpuqrMhXwcLLUd5tvQ4euBHCdh7wGlDfNz8vbu/iI=" crossorigin="anonymous"></script>
      <script src="https://cdnjs.cloudflare.com/ajax/libs/fancybox/3.5.7/jquery.fancybox.min.js" integrity="sha256-yt2kYMy0w8AbtF89WXb2P1rfjcP/HTHLT7097U8Y5b8=" crossorigin="anonymous"></script>

      

      
        
        <script src="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/9.18.1/highlight.min.js" integrity="sha256-eOgo0OtLL4cdq7RdwRUiGKLX9XsIJ7nGhWEKbohmVAQ=" crossorigin="anonymous"></script>
        
        <script src="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/9.18.1/languages/r.min.js"></script>
        
      

    

    
    

    
    
    <script>const code_highlighting = true;</script>
    

    
    
    <script>const isSiteThemeDark = false;</script>
    

    
    
    
    
    
    
    <script>
      const search_config = {"indexURI":"/mesothelioma/index.json","minLength":1,"threshold":0.3};
      const i18n = {"no_results":"No results found","placeholder":"Search...","results":"results found"};
      const content_type = {
        'post': "Posts",
        'project': "Projects",
        'publication' : "Publications",
        'talk' : "Talks"
        };
    </script>
    

    
    
    <script src="https://cdnjs.cloudflare.com/ajax/libs/anchor-js/4.1.1/anchor.min.js" integrity="sha256-pB/deHc9CGfFpJRjC43imB29Rse8tak+5eXqntO94ck=" crossorigin="anonymous"></script>
    <script>
      anchors.add();
    </script>
    

    
    
    <script id="search-hit-fuse-template" type="text/x-template">
      <div class="search-hit" id="summary-{{key}}">
      <div class="search-hit-content">
        <div class="search-hit-name">
          <a href="{{relpermalink}}">{{title}}</a>
          <div class="article-metadata search-hit-type">{{type}}</div>
          <p class="search-hit-description">{{snippet}}</p>
        </div>
      </div>
      </div>
    </script>
    

    
    
    <script src="https://cdnjs.cloudflare.com/ajax/libs/fuse.js/3.2.1/fuse.min.js" integrity="sha256-VzgmKYmhsGNNN4Ph1kMW+BjoYJM2jV5i4IlFoeZA9XI=" crossorigin="anonymous"></script>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/mark.js/8.11.1/jquery.mark.min.js" integrity="sha256-4HLtjeVgH0eIB3aZ9mLYF6E8oU5chNdjU6p6rrXpl9U=" crossorigin="anonymous"></script>
    

    
    

    
    

    
    
    <script id="dsq-count-scr" src="https://procovid19.disqus.com/count.js" async></script>
    

    
    
    
    
    
    
    
    
    
      
    
    
    
    
    <script src="/mesothelioma/js/academic.min.37431be2d92d7fb0160054761ab79602.js"></script>

    






  
  

  
<div id="modal" class="modal fade" role="dialog">
  <div class="modal-dialog">
    <div class="modal-content">
      <div class="modal-header">
        <h5 class="modal-title">Cite</h5>
        <button type="button" class="close" data-dismiss="modal" aria-label="Close">
          <span aria-hidden="true">&times;</span>
        </button>
      </div>
      <div class="modal-body">
        <pre><code class="tex hljs"></code></pre>
      </div>
      <div class="modal-footer">
        <a class="btn btn-outline-primary my-1 js-copy-cite" href="#" target="_blank">
          <i class="fas fa-copy"></i> Copy
        </a>
        <a class="btn btn-outline-primary my-1 js-download-cite" href="#" target="_blank">
          <i class="fas fa-download"></i> Download
        </a>
        <div id="modal-error"></div>
      </div>
    </div>
  </div>
</div>

</body>
</html>
